Skip to main content
. 2022 Dec 15;132(24):e160767. doi: 10.1172/JCI160767

Figure 7. Pharmacological inhibition of FOXO1 suppresses MCL progression in vivo.

Figure 7

(A) Experimental design of the in vivo treatment. (B) Bioluminescent imaging of CCMCL1 MCL recipient mice at the indicated day after initiation of treatment with cpd10 (100 mg/kg/d) or vehicle control. (C) Quantification of bioluminescent imaging responses to cpd10 treatment. Mean values of vehicle-treated (n = 5) and cpd10-treated (n = 6) mice are shown. Data represent mean ± SEM (n = 5 or 6). Results are representative of 2 independent experiments. Statistical analysis was performed using 2-tailed unpaired Student’s t test. ***P < 0.0005. (D) Kaplan-Meier survival curves of control and cpd10-treated mice. Statistical significance was determined using a log-rank test. (E) RT-qPCR analysis of indicated human genes in vehicle- and cpd10-treated spleens of CCMCL1 MCL recipient mice. Data represent mean ± SEM (n = 3 or 4). Results are representative of 2 independent experiments. Statistical analysis was performed using 2-tailed unpaired Student’s t test. **P < 0.005, ***P < 0.0005. (F) Predicted model of MCL lineage-survival transcriptional program and its dissolution following targeted inhibition of FOXO1.